Literature DB >> 9914943

Type I interferons.

E De Maeyer1, J De Maeyer-Guignard.   

Abstract

Type I interferons (IFNs) constitute a family of structurally related proteins that are all derived from the same ancestral gene and act on a common cell-surface receptor. Contrary to many other cytokines, the production of type I IFNs is not a specialized function, and all cells in the organism can produce them, usually as a result of induction by viruses, via the formation of double-stranded RNA. Type I IFNs are indeed responsible for the first line of defense during virus infection and act through the induction of a great number of proteins. Of these, at least thirty have been characterized, and there are probably many more. In addition to their direct antiviral effect, type I IFNs exert a wide variety of other activities, such as for example the induction of various cytokines and the stimulation of different effector cells of the immune system. Due to these pleiotropic effects, recombinant interferons are used in the clinic to treat a variety of diseases, among which cancer, viral hepatitis and multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9914943     DOI: 10.3109/08830189809084487

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  24 in total

Review 1.  Cell receptors and cell signalling.

Authors:  I J Uings; S N Farrow
Journal:  Mol Pathol       Date:  2000-12

Review 2.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 3.  Dendritic cell-mediated T cell polarization.

Authors:  Esther C de Jong; Hermelijn H Smits; Martien L Kapsenberg
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

Review 4.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

5.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 6.  Regulation of effector and memory T-cell functions by type I interferon.

Authors:  Jonathan P Huber; J David Farrar
Journal:  Immunology       Date:  2011-02-14       Impact factor: 7.397

7.  Influenza virus infection induces metallothionein gene expression in the mouse liver and lung by overlapping but distinct molecular mechanisms.

Authors:  K Ghoshal; S Majumder; Q Zhu; J Hunzeker; J Datta; M Shah; J F Sheridan; S T Jacob
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

8.  The inducible nitric-oxide synthase (iNOS)/Src axis mediates Toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-β synthesis in macrophages.

Authors:  Ming-Yu Hsieh; Miao Ying Chang; Yen-Jen Chen; Yung Kuo Li; Tsung-Hsien Chuang; Guann-Yi Yu; Chun Hei Antonio Cheung; Hui-Chen Chen; Ming-Chei Maa; Tzeng-Horng Leu
Journal:  J Biol Chem       Date:  2014-02-13       Impact factor: 5.157

9.  The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.

Authors:  Jim B Boonyaratanakornkit; Emmalene J Bartlett; Emerito Amaro-Carambot; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

10.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.